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Abstract
Background—Outcome analyses in large administrative databases are ideal for rare diseases 
such as Becker and Duchenne muscular dystrophy. Unfortunately, Becker and Duchenne do not 
yet have specific ICD-9/ICD-10 codes. We hypothesized that an algorithm could accurately 
identify these patients within administrative data and improve assessment of cardiovascular 
morbidity.
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Methods—Hospital discharges (n=13,189) for patients with muscular dystrophy (ICD-9 359.1) 
were identified in the Pediatric Health Information System database. An identification algorithm 
was created then validated at 3 institutions. Multivariable generalized linear mixed effects models 
used to estimate the associations of length of stay, hospitalization cost, and 14-day readmission 
with age, encounter severity, and respiratory disease accounting for clustering within a hospital.
Results—The identification algorithm improved identification of Becker and Duchenne patients 
from 55% (359.1 alone) to 77%. On bivariate analysis, left ventricular dysfunction and arrhythmia 
were associated with increased cost of hospitalization, length of stay, and mortality (p<0.001). 
After adjustment, Becker and Duchenne patients with left ventricular dysfunction and arrhythmia 
had increased length of stay (rate ratio 1.4 and 1.2, p<0.001 and p=0.004) and cost (rate ratio 1.4 
and 1.4, both p<0.001).
Conclusions—Our algorithm accurately identifies patients with Becker and Duchenne and can 
be used for future analysis of administrative data. Our analysis demonstrates the significant effects 
of cardiovascular disease on length of stay and hospitalization cost in Becker and Duchenne 
patients. Better recognition of the contribution of cardiovascular disease during hospitalization 
with earlier, more intensive evaluation and therapy may help improve outcomes in this patient 
population.
Keywords
Duchenne muscular dystrophy; Becker muscular dystrophy; Pediatric Health Information System; 
Left ventricular dysfunction; Arrhythmia; Cardiomyopathy
1. INTRODUCTION
Becker and Duchenne muscular dystrophy are the most common muscular dystrophies, with 
an incidence of 1 in 18500 and 1 in 4700 live male births, respectively.1, 2 Patients with 
Becker and Duchenne muscular dystrophy have a mutation in the DMD gene that leads to a 
deficiency or absence of dystrophin protein.3, 4 This results in skeletal muscle weakness and 
loss of ambulation, usually in the second decade of life in Duchenne muscular dystrophy and 
later in life in the milder Becker muscular dystrophy. Both reduced and absent dystrophin 
also leads to the development of cardiomyopathy resulting in progressive left ventricular 
dysfunction.5, 6
Understanding of the clinical importance of Becker and Duchenne cardiomyopathy has 
increased significantly over the past few decades. This is primarily due to improvements in 
care, which have increased life expectancy in patients with Duchenne muscular dystrophy 
and unmasked the cardiovascular phenotype.7 The preponderance of Becker and Duchenne 
research focuses on skeletal muscle weakness, but cardiovascular disease is now one of the 
leading causes of death in patients with Duchenne muscular dystrophy.8 Highlighting the 
effects of cardiovascular disease on inpatient morbidity (length of stay, cost of 
hospitalization, readmission rate) in patients with Becker and Duchenne may help improve 
recognition of the problems associated with cardiovascular disease. Moreover, identifying 
risk factors leading to increased length of stay, cost of hospitalization, and readmission rates 
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in this population can increase recognition and potentially improve outcomes in future 
admissions.
Because Becker and Duchenne muscular dystrophy are relatively rare, the true impact of 
cardiovascular disease can be difficult to determine. Research using large administrative 
databases can overcome these issues. However, using the International Classification of 
Disease (ICD)-9 billing codes, Becker and Duchenne muscular dystrophy are coded as 
359.1, a non-specific code that also encompasses multiple other neuromuscular diagnoses 
(Table 1). This non-specific coding can make analysis problematic. Indeed, a recent 
manuscript using the Pediatric Health Information System database to evaluate the effect of 
cardiovascular disease in Duchenne muscular dystrophy was limited by this non-specific 
coding.9 We hypothesized that, by creating a novel list of exclusion criteria which could be 
validated, patients with Becker and Duchenne muscular dystrophy could be more accurately 
identified within an administrative and billing database, allowing for the current study and 
future assessments in this patient population. To demonstrate the potential utility of this 
technique, we used the Pediatric Health Information System database to assess 
cardiovascular risk factors associated with increased length of stay, cost of hospitalization, 
and 14-day readmission in patients with Becker and Duchenne muscular dystrophy.
2. MATERIALS AND METHODS
2.1 Pediatric Health Information System Database and Identification Algorithm
This multicenter retrospective cohort study utilized administrative data from the Pediatric 
Health Information System database. The database contains inpatient, emergency 
department, ambulatory surgery, and observation encounters from 49 tertiary children’s 
hospitals in the United States. Data are de-identified at the time of submission and are 
subjected to reliability and validity checks by participating hospitals, Children’s Hospital 
Association (Lenexa, KS), and Truven Health Analytics (Ann Arbor, MI) before inclusion in 
the database. Patients are assigned up to 41 ICD-9/10 diagnosis and procedure codes, and 
consistently encrypted medical record numbers allow longitudinal tracking of patients across 
encounters to the same hospital. The Pediatric Health Information System database 
represents approximately 15% of the national pediatric hospitalizations and 46.4% of 
children’s hospitals’ total volume.
The Institutional Review Boards of Vanderbilt University Medical Center, Nationwide 
Children’s Hospital, and Children’s National Medical Center approved this study. Using 
ICD-9 diagnosis codes (conversion to ICD-10 codes occurred in the last quarter of 2015), an 
algorithm of exclusion criteria termed the “identification algorithm” was created to improve 
the identification of patients with Becker and Duchenne muscular dystrophy. The 
effectiveness of the algorithm was evaluated by “re-identification” of patients from three 
sites. The electronic medical record was queried to determine the diagnosis and gender of all 
patients with an ICD-9 code of 359.1 and the diagnosis of the remaining patients after the 
identification algorithm was applied.
The algorithm was constructed to optimize the specificity of identifying patients with Becker 
and Duchenne muscular dystrophy. Given the size of the Pediatric Health Information 
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System database, investigators determined that incorrectly excluding patients with Becker 
and Duchenne muscular dystrophy was preferable to incorrectly including patients with an 
alternate diagnosis. The goal at the outset of the study was to construct an algorithm where 
at least 80% of remaining patients carried a diagnosis of Becker and Duchenne muscular 
dystrophy. All patients with an ICD-9 of 359.1 were initially included. In order to eliminate 
errors in coding, patients with a change in primary diagnosis to a different 359.x code were 
excluded. A set of clinical characteristics was created to exclude neuromuscular conditions 
other than Becker and Duchenne muscular dystrophy. Briefly, patients with severe disease at 
a young age felt unlikely to be due to Becker or Duchenne were eliminated (early mortality, 
ventilatory support, or cardiovascular disease). Because the majority of Becker and 
Duchenne patients do not require gastrostomy tubes until later in life, and only 15% of 
patients were older than 18 in this cohort, all patients with gastrostomy tubes were removed. 
Other neurologic diagnoses that could have been mistakenly coded as 359.1 were removed, 
as were diagnoses that came up in an initial search of 359.1 at one institution. Patients 
undergoing heart transplantation were not excluded as transplantation has been performed in 
the Becker muscular dystrophy population.
2.2 Primary Analysis
The primary analysis was performed on the entire cohort (49 hospitals) after application of 
the identification algorithm. Discharges in patients with muscular dystrophy were identified 
in Pediatric Health Information System from January 1, 2003 - September 30, 2015 (chosen 
based on transition from ICD-9 to ICD-10). Patients with left ventricular dysfunction and 
arrhythmia were identified using ICD-9 codes (Supplementary Table S1). Patients requiring 
respiratory support (Table S1) were also identified. Discharges that occurred under 1 year of 
age were eliminated from the analysis as these admissions were more likely to reflect 
neonatal and infant hospitalizations unrelated to the diagnosis of Becker and Duchenne 
muscular dystrophy. The primary outcome measures included length of stay, cost of 
hospitalization (estimated from charges using hospital/year specific ratios of cost to charge), 
14-day all-cause readmission, and in-hospital mortality.
2.3 Statistical Analysis
To assess the effectiveness of the identification algorithm, the percentage of the patients with 
Becker and Duchenne muscular dystrophy before and after application of the algorithm was 
calculated for the 3 sites. The percentage of patients with Becker and Duchenne muscular 
dystrophy who were incorrectly excluded was also calculated.
For the primary analysis on the entire Pediatric Health Information System cohort, pertinent 
demographic information was summarized and bivariate analyses were performed to assess 
the relationships of each demographic and length of stay (stratified by <2 days vs. 2+ days) 
using chi-square and Wilcoxon Rank Sum tests. Next, separate generalized linear mixed 
effects models assuming either an exponential distribution (length of stay and cost) or a 
binomial distribution (14-day readmission and mortality) for the outcome were used to 
estimate the adjusted associations with age, encounter severity, and respiratory disease. A 
random intercept was used to account for correlation arising from taking repeated 
measurements on the same hospital. Results are summarized using the rate ratio or odds 
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ratio with corresponding 95% confidence intervals. Statistical analyses were performed 
using SAS v.9.4 (SAS Institute, Cary, NC), and a p-value < 0.05 was considered statistically 
significant.
3. RESULTS
3.1 Identification Algorithm
The final identification algorithm is listed in Table 2. At the 3 Pediatric Health Information 
System sites, we performed a detailed assessment of our algorithm by re-identifying the 289 
patients with an ICD-9 of 359.1 and determining true diagnosis using the local electronic 
medical record. Of the 289 patients, 55% (158) had a diagnosis of Becker and Duchenne 
muscular dystrophy prior to the application of the identification algorithm. Excluding female 
patients increased this to 68% (158 of 233). Applying the identification algorithm increased 
the accuracy of correct Becker and Duchenne muscular dystrophy diagnosis to 77% (131 of 
170) by excluding 27 patients with Becker and Duchenne muscular dystrophy (17%) and 91 
patients without Becker and Duchenne muscular dystrophy (70% of non-Becker and non-
Duchenne muscular dystrophy patients). Of note, two sites provided a breakdown of Becker 
muscular dystrophy vs Duchenne muscular dystrophy, and only 5% of included patients at 
those sites had Becker muscular dystrophy. We hypothesize that this preponderance of 
Duchenne muscular dystrophy is due to the relatively higher frequency in the general 
population and earlier cardiomyopathy as well as a lower frequency of admission in children 
with Becker muscular dystrophy.
3.2 Demographics
In the entire Pediatric Health Information System cohort, a total of 3,430 unique patients 
with 13,189 discharges from 49 hospitals were identified with an ICD-9 of 359.1. After 
application of the identification algorithm, 1,916 patients and 4014 discharges remained.
The majority of discharges (89.5%) were to home, 4% were discharged to a skilled facility, 
3.1% to home health service, and 2.2% (90 discharges) died in the hospital (4.7% of 
patients). As expected, neuromuscular and cardiovascular codes were the most common, 
with 90% of discharges having at least one neuromuscular code and 30% having at least one 
cardiovascular code. In addition, 22% had a code for congenital or genetic defects, 21% had 
a code suggesting technology dependence, and 7% had a code denoting respiratory disease. 
A total of 26% of discharges had a diagnosis of left ventricular dysfunction, 8% arrhythmia, 
and 21% respiratory disease. Further demographic data are reported in Table 3.
3.3 Primary Analysis
Bivariate analysis for the predictors left ventricular dysfunction, arrhythmia, and respiratory 
disease for the outcomes of length of stay, cost of hospitalization, 14-day readmission, and 
mortality are shown in Table 4. We also considered adjusted models controlling for age, 
encounter severity, respiratory disease, and hospital. The adjusted association of predictors 
with mortality was not estimated because there were too few events to support a 
multivariable model. However, for length of stay we found significant adjusted association 
with left ventricular dysfunction (rate ratio = 1.4, 95% CI [1.3, 1.5], p<0.001), arrhythmia 
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(rate ratio = 1.2, 95% CI [1.1, 1.4], p=0.004), and respiratory disease (rate ratio = 1.6, 95% 
CI [1.5, 1.8], p<0.001) (Table 5). We also found significant adjusted association for cost of 
hospitalization with left ventricular dysfunction (rate ratio = 1.2, 95% CI [1.1, 1.3], 
p<0.001), arrhythmia (rate ratio = 1.4, 95% CI [1.2, 1.6], p<0.001), and respiratory disease 
(rate ratio = 1.4, 95% CI [1.3, 1.5], p<0.001). Becker and Duchenne muscular dystrophy 
patients with respiratory disease had decreased rates of 14-day readmission (odds ratio = 0.6, 
95% CI [0.3,1], p=0.045), while left ventricular dysfunction (odds ratio = 1, 95% CI 
[0.7,1.3], p=0.780) and arrhythmia (odds ratio = 1.5, 95% CI [0.9, 2.5], p=0.128) were not 
significantly associated with readmission. The combination of arrhythmia and left 
ventricular dysfunction (cardiovascular disease) demonstrated similar effects for 
hospitalization cost and length of stay (Supplementary Table S2).
4. DISCUSSION
These results demonstrate that: 1) the application of our identification algorithm confirmed 
by direct validation significantly increases the specificity for Becker and Duchenne muscular 
dystrophy in the Pediatric Health Information System database and 2) left ventricular 
dysfunction, arrhythmia, and respiratory disease play significant, independent roles in 
predicting inpatient morbidity and, in the bivariate model, mortality. Given the rarity of 
Becker and Duchenne muscular dystrophy, a method that allows researchers to leverage 
large databases is critical to improving outcomes. Analysis of the Pediatric Health 
Information System database may help identify areas of improvement that could lead to a 
decrease in the costs of hospitalization for patients with Becker and Duchenne muscular 
dystrophy. Moreover, these data can serve as a baseline appraisal, allowing for the 
assessment of future shifts in outcome resulting from modifications in therapies or changes 
to standards of care in Becker and Duchenne muscular dystrophy. To allow for future 
analyses, we have translated our exclusion criteria to ICD-10 diagnostic codes 
(Supplementary Table S3).
The ICD-9 billing code that includes Becker and Duchenne muscular dystrophy also 
includes many other diagnoses. Fortunately, this will be rectified in October of 2018 with a 
new ICD-10 code. However, given that this manuscript used over 12 years of data from the 
Pediatric Health Information System, it will take an extended period of time for that change 
to be relevant. The algorithm reported here will remain critical for future analyses and will 
facilitate analysis of historical trends. In addition, similar methods can be used to evaluate 
morbidity and mortality due to other forms of muscular dystrophy coded as 359.1.
These data further emphasize the importance of cardiovascular disease in Becker and 
Duchenne muscular dystrophy. It is notable that 30% of the patients in this analysis had at 
least one cardiovascular code while only 7% had a code for respiratory disease. 
Cardiovascular disease has become increasingly recognized as a major contributor of 
mortality.8,10 Punnoose et al recently evaluated the association between cardiovascular 
disease and morbidity and mortality in the Pediatric Health Information System database, 
though their analysis was limited by the poor specificity of ICD-9 coding for Duchenne 
muscular dystrophy.9 Their study also demonstrated that ventricular tachycardia and heart 
failure, as well as chronic ventilator use, were risk factors for the combined outcome of 
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cardiac arrest or death. Their exclusions likely improved specificity for Duchenne muscular 
dystrophy but are less extensive than the algorithm we present here, and they were unable to 
directly validate the effectiveness of their exclusion criteria. The prevalence of 
cardiomyopathy increases significantly as Becker and Duchenne muscular dystrophy 
patients age, with previous studies suggesting that >60% of patients over 18 years of age 
have cardiomyopathy.5, 11 Unfortunately, while official recommendations state that 
echocardiographic screening should begin by 6 years of age, Spurney et al demonstrated that 
a surprisingly large portion of Duchenne muscular dystrophy patients had not undergone 
echocardiography by 10 years of age.11 Moreover,that study revealed that over half of 
Duchenne muscular dystrophy patients with a diagnosis of cardiomyopathy were not 
prescribed appropriate anti-congestive therapy. Taken together, these data suggest that the 
focus of care in Becker and Duchenne muscular dystrophy must shift towards earlier 
detection and prevention of cardiovascular disease. Raising awareness of the risks of 
cardiovascular disease in Becker and Duchenne muscular dystrophy patients admitted to the 
hospital may lead to earlier recognition and more aggressive therapy, eventually improving 
outcomes.
Our data confirm that respiratory disease continues to play a significant role in inpatient 
morbidity and mortality in patients with Becker and Duchenne muscular dystrophy. Multiple 
authors have reported the improved life expectancy associated with ventilation in Duchenne 
muscular dystrophy.7, 8, 12 While survival has increased significantly with these 
interventions, respiratory disease of any kind, including acute respiratory complications and 
the need for chronic ventilation, significantly increased the odds of a longer length of stay 
and higher cost of hospitalization. Moreover, the complex interactions between 
cardiovascular and respiratory disease likely plays an important role in Becker and 
Duchenne muscular dystrophy inpatient morbidity.
Multiple reports have demonstrated the increased cost of both Duchenne and Becker 
muscular dystrophy compared with the general population. Thayer et al demonstrated a 10-
fold increase in costs in a small cohort of 75 Duchenne muscular dystrophy patients by 
analyzing claims from a single health plan.13 Surveys of families in multiple countries have 
demonstrated increases in both healthcare costs and out of pocket costs to families of Becker 
and Duchenne muscular dystrophy patients.14–16 In general, costs increase with increasing 
age/progression of disease.14, 15 Costs have also been shown to be increased in Duchenne 
muscular dystrophy patients with tracheostomy compared to those on continuous non-
invasive ventilation.17 However, only our data and that of Punnoose have stratified costs 
based on cardiovascular disease.9 Awareness of the increased cost associated with both 
arrhythmia and left ventricular dysfunction could allow for improvement in Becker and 
Duchenne muscular dystrophy costs with earlier and more aggressive detection and therapy. 
Not surprisingly, our data also demonstrated significantly increased length of stay and cost 
of hospitalization with advancing age in Becker and Duchenne muscular dystrophy, even 
when correcting for arrhythmia, left ventricular dysfunction, and respiratory disease.
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4.1 Limitations
This study does have inherent limitations. As with any large database, data could be 
incomplete, incorrect, or missing. The Pediatric Health Information System does not capture 
events that occur outside a hospital encounter and does not include physician fees as part of 
the cost analysis. In addition, the Pediatric Health Information System only captures events 
that occur in children’s hospitals. Specific to this study, our algorithm prioritized 
identification of Becker and Duchenne muscular dystrophy patients with the knowledge that 
some patients would be incorrectly excluded. However, re-identification demonstrated that 
17% of Becker and Duchenne muscular dystrophy patients were incorrectly excluded while 
70% of non-Becker and Duchenne muscular dystrophy were excluded. The algorithm we 
present to better identify Becker and Duchenne muscular dystrophy patients does still 
include patients without Becker and Duchenne muscular dystrophy, but this number is 
significantly lower after our exclusion criteria and we feel the advantages of using larger 
numbers for this and future studies will outweigh this limitation. We also evaluated an 
algorithm that increased the identification of Becker and Duchenne muscular dystrophy 
patients to 79% (Supplementary Table 4), but this algorithm excluded a much larger number 
of patients with Becker’s and Duchenne’s (35%), so the less aggressive algorithm was used 
for the final analysis. Of note, the results of the primary analysis were not significantly 
different between algorithms.
4.2 Conclusions
We present an algorithm for improving identification of Becker and Duchenne muscular 
dystrophy patients using an administrative database. Initial analysis demonstrated a large 
number of Becker and Duchenne muscular dystrophy patients with cardiovascular codes and 
increased cost and length of stay in patients with both arrhythmia and left ventricular 
dysfunction. This algorithm can be used to analyze other outcomes of interest in patients 
with Becker and Duchenne muscular dystrophy and can also serve as a baseline to assess 
changes in therapy over time.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1:
List of Diagnoses Included in ICD-9 Code 359.1
Facioscapulohumeral muscular dystrophy Hereditary, progressive muscular dystrophy
Landouzy-Déjérine Leyden-Möbius
Pseudohypertrophic muscular dystrophy Distal muscular dystrophy
Duchenne’s muscular dystrophy Fascioscapulohumeral muscular dystrophy
Duchenne-Griesinger Limb-girdle muscular dystrophy
Erb (-Landouzy) Ocular muscular dystrophy
Hereditary neuromuscular NEC Oculopharyngeal muscular dystrophy
Duchenne’s pseudohypertrophy, muscles Pelvicrural atrophic muscular dystrophy
Erb’s dystrophy Progressive ophthalmoplegic muscular dystrophy
Gower’s muscular dystrophy Scapuloperoneal ophthalmoplegic muscular dystrophy
Emery Dreifuss muscular dystrophy Becker’s muscular dystrophy
Kearns-Sayre syndrome (disorder) Mitochondrial ocular myopathy
Muscular dystrophy Neuropathic muscular dystrophy
Restrictive lung disease due to muscular dystrophy Congenital myopathy
Congenital muscular dystrophy
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Table 2:
Identification Algorithm
Patients Patients
Excluded Remaining
Inclusion
 ICD-9=359.1 3430
Exclusions
 Cerebral degenerations (330.x), Spinocerebellar disease (334.x), Anterior horn cell disease (335.x), or Hereditary 
and idiopathic peripheral neuropathy (356.x) 387 3043
 Changed to another 359.x code 405 2638
 G-tubea 458 2180
 Ophthalmoplegia 2 2178
 Pigmentary retinopathy 0 2178
 Mortality age<5 8 2170
 Ventilation <5 years of age (tracheostomy or CPAP/BIPAPb) 0 2170
 AICDc <10 years of age 1 2169
 Arrhythmia <5 years of age 7 2162
 Cardiovascular disease <5 years of age 6 2156
 Female 224 1932
 Age <1 year at time of only encounter 16 1916
agastrostomy tube (G-tube)
bContinuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP)
cAutomatic implantable cardioverter-defibrillator (AICD)
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Table 3:
Demographics
Prior to Exclusions Post Exclusions
N Discharges 13189 4014
N Patients 3430 1916
Discharge contained 7538 (57.2%) 3522 (87.7%)
ICD-9 code 359.1
Age: Median [IQR] 13 [6, 17] 14 [11, 17]
Age <1 640 (4.9%)
1–4 1966 (14.9%) 159 (4%)
5–9 2105 (16%) 504 (12.6%)
10–14 3344 (25.4%) 1431 (35.7%)
15–18 3124 (23.7%) 1293 (32.2%)
19+ 2010 (15.2%) 627 (15.6%)
Gender Male 9746 (73.9%) 4014 (100%)
Race Non-Hispanic 7900 (59.9%) 2590 (64.5%)
White
Non-Hispanic Black 1139 (8.6%) 289 (7.2%)
Hispanic 2826 (21.4%) 730 (18.2%)
Asian 313 (2.4%) 81 (2%)
Other 1011 (7.7%) 324 (8.1%)
Discharge Disposition Home Health 692 (5.2%) 123 (3.1%)
Service
Home 11690 (88.6%) 3593 (89.5%)
Skilled Facility 385 (2.9%) 159 (4%)
Died 210 (1.6%) 90 (2.2%)
Other 212 (1.6%) 49 (1.2%)
CCCs v.2.0 Neuromuscular 11202 (84.9%) 3594 (89.5%)
Cardiovascular 3189 (24.2%) 1192 (29.7%)
Disease
Respiratory 3248 (24.6%) 272 (6.8%)
Renal 458 (3.5%) 65 (1.6%)
Gastrointestinal 4484 (34%) 74 (1.8%)
Hematology and 224 (1.7%) 61 (1.5%)
Immunodeficiency
Metabolic 1125 (8.5%) 224 (5.6%)
Congenital or 3642 (27.6%) 896 (22.3%)
genetic defect
Malignancy 158 (1.2%) 68 (1.7%)
Technology 6432 (48.8%) 849 (21.2%)
Dependence
Transplant 213 (1.6%) 106 (2.6%)
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Prior to Exclusions Post Exclusions
Any 12435 (94.3%) 3734 (93%)
Length of Stay: 3 [1, 7] 2 [1, 6]
Median [IQR]
Length of Stay a. 0–1 days 4007 (30.4%) 1579 (39.3%)
b. 2–3 days 3071 (23.3%) 811 (20.2%)
c. 4–6 days 2367 (17.9%) 697 (17.4%)
d. ≥ 7 days 3744 (28.4%) 927 (23.1%)
Decreased left ventricular function 2419 (18.3%) 1050 (26.2%)
Arrhythmia 938 (7.1%) 301 (7.5%)
Respiratory support 4944 (37.5%) 853 (21.3%)
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Table 4A:
Bivariate Analysis for Decreased Left Ventricular (LV) Function
Decreased LV Function
No Yes p
N Discharges 2964 (73.8%) 1050 (26.2%)
Length of Stay 2 5 <.001
(days) [1, 5]a [2,10]
Cost (dollars) 6119 16162 <.001
[3317, 17275] [7038, 45282]
14 Day 0.557
Readmission 158 (5.3%) 61 (5.8%)
Mortality 29 (1%) 61 (5.8%) <0.001
a
Interquartile range
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Table 4B:
Bivariate Analysis for Arrhythmia
Arrhythmia
No Yes p
N Discharges 3713 (92.5%) 301 (7.5%)
Length of Stay 2 5 <.001
(days) [1, 6] [2, 13]
Cost (dollars) 7324 25189 <.001
[3585, 20906] [9330, 61637]
14 Day 0.046
Readmission 195 (5.3%) 24 (8%)
Mortality 45 (1.2%) 45 (15%) <0.001
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Table 4C:
Bivariate analysis for respiratory disease
Respiratory Disease
No Yes p
N Discharges 3161 (78.7%) 853 (21.3%)
Length of Stay 2 6 [ <.001
(days) [1, 5] 3, 13]
Cost (dollars) 6161 22222 <.001
[3390, 15860] [9024, 61141]
14 Day 0.347
Readmission 178 (5.6%) 41 (4.8%)
Mortality 30 (0.9%) 60 (7%) <0.001
Cardiol Young. Author manuscript; available in PMC 2019 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Soslow et al. Page 17
Table 4D:
Number of Discharges with Each Combination of Exposure
Decreased left ventricular function/cardiomyopathy Respiratory
Arrhythmia support N %
No No No 2440 60.8
No No Yes 416 10.3
No Yes No 72 1.8
No Yes Yes 36 0.9
Yes No No 541 13.5
Yes No Yes 316 7.9
Yes Yes No 108 2.7
Yes Yes Yes 85 2.1
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Table 5A:
Generalized linear mixed effects model with LOS as outcome measure
LOS
Rate Ratio (95% CI) p
Age 1–4 Reference
5–9 1 (0.8,1.1) 0.629
10–14 1.2 (1,1.4) 0.034
15–18 1.4 (1.1,1.6) 0.001
19+ 1.4 (1.2,1.7) <.001
Decreased LV function Yes 1.4 (1.3,1.5) <.001
No Reference
Arrhythmia Yes 1.2 (1.1,1.4) 0.004
No Reference
Respiratory support Yes 1.6 (1.5,1.8) <.001
No Reference
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Table 5B:
Generalized linear mixed effects model with cost of hospitalization as outcome measure
Cost
Rate Ratio (95% CI) p
Age 1–4 Reference
5–9 1.1 (0.9,1.3) 0.324
10–14 1.5 (1.3,1.8) <.001
15–18 1.7 (1.5,2) <.001
19+ 1.9 (1.6,2.3) <.001
Decreased LV function Yes 1.2 (1.1,1.3) <.001
No Reference
Arrhythmia Yes 1.4 (1.2,1.6) <.001
No Reference
Respiratory support Yes 1.4 (1.3,1.5) <.001
No Reference
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Table 5C:
Generalized estimating equation with 14-day readmission as outcome measure
14-Day
Readmission
Odds Ratio (95% CI) p
Age 1–4 Reference
5–9 0.8 (0.3, 1.9) 0.598
10–14 0.7 (0.3, 1.3) 0.207
15–18 0.8 (0.4, 1.6) 0.567
19+ 1.4 (0.5, 3.6) 0.494
Decreased LV function Yes 1 (0.7, 1.3) 0.780
No Reference
Arrhythmia Yes 1.5 (0.9, 2.5) 0.128
No Reference
Respiratory support Yes 0.6 (0.3, 1) 0.045
No Reference
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